Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kymab Group Ltd.

www.kymab.com

Latest From Kymab Group Ltd.

Lundbeck Leads $50m Fund Raise For CRISPR Microbiome StartUp

A Danish company with a novel approach to gene editing for antibacterials has raised $50m in a series A round, using the cash injection to advance its ambition to be testing drug candidates in humans by 2021.

Financing StartUps and SMEs

China's EpimAb Advances Bispecific Antibody To Rival Janssen Candidate

EpimAb's business development officer tells Scrip dosing has started in a Phase I/II trial assessing the China-based biotech's lead cancer molecule EMB01, an EGFR-cMET bispecific antibody.

StartUps and SMEs Companies

Crescendo Raises $70m In Largest European Biotech Series B Of Year

Crescendo Biologics raises $70m to take its first Humabody asset into clinical trials for prostate cancer; the company’s CEO Peter Pack tells Scrip more about its diverse financiers and plans for big pharma partnering in the future.

Financing Business Strategies

Gates Foundation’s $40m Incentivizes Cancer Specialist Immunocore To Develop TB, HIV Drugs

Oxford, UK-based Immunocore, which is developing immunotherapies against cancer, has secured $40m in funding from the Bill & Melinda Gates Foundation to boost its research activities in infectious diseases. The company hopes to develop novel therapeutics to reduce treatment timelines and improve outcomes for patients with HIV and TB.

Deals Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
    • Transgenics
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Kymab Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Kymab Group Ltd.
  • Senior Management
  • Simon Sturge, PhD, CEO
    Anne Hyland, CFO & Secretary
    Nigel Clark, PhD, SVP, Bus. Dev.
    Allan Bradley, PhD, CSO
  • Contact Info
  • Kymab Group Ltd.
    Phone: (44) 1223 833301
    Babraham Research Campus
    Bennet B390
    Cambridge, CB22 3AT
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register